Background: Current and recent use of the nucleoside reverse transcriptase inhibitor, abacavir (ABC) has been associated with increased risk of myocardial infarction, with both endothelial dysfunction and altered platelet reactivity with ABC use implicated. Methodology: Changes in markers of platelet function were examined in a sub-study of the SWIFT trial, a prospective, randomised, 48-week trial of virally suppressed, protease-inhibitor-treated, HIV-1 positive subjects randomised to switch abacavir/ lamivudine (ABC/3TC) to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or remain on ABC/3TC. Soluble glycoprotein VI (sGPVI), a marker of collagen-mediated platelet activation and soluble P-selectin (sP-sel), involved in platelet-leucocyte interactions, were measured by enzyme-linked immunosorbent assays (Meso Scale Discovery, Rockville, MD) in stored plasma samples collected at weeks 0, 4, 12, 24, 36 and 48. Changes in platelet markers over time were assessed using mixed effect models. Data are mean [SD] unless specified. Results: Of 312 patients (age 46 [9.3] years, 85% male, 65% Caucasian), 156 switched to TDF/FTC. Groups were well matched for baseline demographic and laboratory data including CD4+ T-cell count (TDF/TFC versus ABC/3TC, 548 [257], 582 [287] /μl respectively), platelet count (244 [58], 253 [72] x103/μl), total cholesterol (5.4 [1.2], 5.3 [1.0] mmol/L), LDL (3.1 [1.0], 3.1 [0.8] mmol/L) and HDL (1.29 [0.38], 1.31 [0.42] mmol/L) cholesterol and history of dyslipidaemia or hypertension. There were no between-group differences in baseline sGPVI (mean (SEM) 3.75 [0.25] ng/ml versus 3.61 [0.22] ng/ml, p=0.68) or sP-sel (65.0 [2.2] ng/ml versus 69.2 [2.9], p=0.25) and no between-group differences in change in sP-sel from baseline to 48 weeks (p=0.37, figure 1b). However, relative to the ABC/3TC group, sGPVI increased to week 48 in those who switched to TDF/FTC (effect size +0.012 (95%CI 0.0041, 0.02), between group p=0.002, figure 1a). This effect persisted when corrected for age, ethnicity, history of dyslipidaemia or hypertension, baseline CD4+ T-cell and platelet count and change from baseline to week 48 in creatinine, LDL, HDL, CD4+ T-cell and platelet count. Conclusions: The observed increases in sGPVI point to changes in intrinsic platelet function with a switch away from ABC/3TC to TDF/FTC. Further mechanistic research is required to determine the relevance of these changes on overall platelet reactivity and cardiovascular disease.